FLC Capital Advisors Invests $278,000 in Sanofi $SNY

FLC Capital Advisors purchased a new position in shares of Sanofi (NASDAQ:SNY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,751 shares of the company’s stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SNY. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi during the 2nd quarter worth $28,000. Accent Capital Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth $29,000. Eastern Bank raised its stake in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Sanofi during the 1st quarter worth $33,000. Finally, Golden State Wealth Management LLC raised its stake in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SNY. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 1.2%

NASDAQ SNY opened at $50.62 on Monday. The stock has a market cap of $124.30 billion, a PE ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The business has a 50 day moving average price of $48.49 and a two-hundred day moving average price of $49.56. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm’s revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.73 EPS. As a group, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.